All In Biotech

Drug Trial Radar · NCT06087835

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants With Chronic Kidney Disease and High Proteinuria

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,835 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,835

Actual

Start

Nov 7, 2023

Primary completion

Feb 18, 2027

Study completion Feb 18, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 95 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria

Conditions

  • Chronic Kidney Disease With High Proteinuria

Interventions

  • Zibotentan/DapagliflozinDrug

    Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to

  • DapagliflozinDrug

    Participants will receive dapagliflozin as per the arms they are randomized to

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in eGFR from baselineTime frame: At month 24

Locations

296 sites in 30 countries. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama

  • Research Site

    Sun City West, Arizona

  • Research Site

    Bakersfield, California

  • Research Site

    Huntington Park, California

  • Research Site

    Los Alamitos, California

  • Research Site

    Los Angeles, California

  • Research Site

    Northridge, California

  • Research Site

    Oxnard, California

  • Research Site

    San Carlos, California

  • Research Site

    San Dimas, California

  • Research Site

    Tarzana, California

  • Research Site

    Victorville, California

  • Research Site

    Arvada, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Boynton Beach, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Hollywood, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Jensen Beach, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Fayetteville, Georgia

  • Research Site

    Champaign, Illinois

  • Research Site

    Chicago, Illinois

  • Research Site

    Hinsdale, Illinois

  • Research Site

    Island Lake, Illinois

  • Research Site

    Skokie, Illinois

  • Research Site

    Bowling Green, Kentucky

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Silver Spring, Maryland

  • Research Site

    Flint, Michigan

  • Research Site

    Flint, Michigan

  • Research Site

    Troy, Michigan

  • Research Site

    City of Saint Peters, Missouri

  • Research Site

    Albany, New York

  • Research Site

    Middletown, New York

  • Research Site

    Orchard Park, New York

  • Research Site

    Greenville, North Carolina

  • Research Site

    Jacksonville, North Carolina

Showing 40 of 296 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.